Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 4/20 | 0.74 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.69 |
| ▸ | PLA2G4A | P47712 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | NPC1 | O15118 | 3/20 | 0.68 |
| ▸ | RAB9A | P51151 | 3/20 | 0.68 |
| ▸ | CALM1 | P0DP23 | 2/20 | 0.68 |
| ▸ | PKM | P14618 | 2/20 | 0.68 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 3/20 | 0.64 |
| ▸ | HPGD | P15428 | 3/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.64 |
| ▸ | GABRP | O00591 | 2/20 | 0.64 |
| ▸ | GABRD | O14764 | 2/20 | 0.64 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.64 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.64 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.64 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11562626 | 0.93 | MAPT (0.72) | TNKSPLA2G2APLA2G4AMAPTNPC1 | |
| SCHEMBL24227267 | 0.88 | PLA2G2A (0.66) | TNKSPLA2G2APLA2G4AMAPTNPC1 | |
| SCHEMBL10626539 | 0.88 | MAPT (0.73) | TNKSPLA2G2APLA2G4AMAPTNPC1 | |
| SCHEMBL31238530 | 0.88 | TNKS (0.66) | TNKSPLA2G2APLA2G4AMAPTNPC1 | |
| SCHEMBL6497044 | 0.88 | TNKS (0.74) | TNKSPLA2G2APLA2G4AMAPTNPC1 | |
| SCHEMBL10629928 | 0.88 | MAPT (0.75) | TNKSPLA2G2APLA2G4AMAPTNPC1 | |
| SCHEMBL11561358 | 0.87 | TNKS (0.60) | TNKSPLA2G2APLA2G4AMAPTNPC1 | |
| SCHEMBL11561640 | 0.86 | GABRP (0.73) | TNKSPLA2G2APLA2G4AMAPTNPC1 | |
| SCHEMBL31238422 | 0.86 | TNKS (0.56) | TNKSPLA2G2APLA2G4AMAPTNPC1 | |
| SCHEMBL11565251 | 0.85 | TNKS (0.55) | TNKSPLA2G2APLA2G4AMAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4083953-A | ANTIALLERGENS | CARLO ERBA, S.P.A. (IT) | 1978-04-11 | — | — | US | claimed |
| CN-111875570-A | Synthetic method of fluorine-containing carboxylic acid flavone-amino acid derivative | 郑州师范学院 | 2020-11-03 | — | — | CN | disclosed |
| US-20110045397-A1 | CHARGE CONTROL AGENT AND RELATED ART | KURODA KAZUYOSHI | 2011-02-24 | — | — | US | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-20100226931-A1 | Compounds for immunopotentiation | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2010-09-09 | — | — | US | disclosed |
| US-7541368-B2 | 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-{3-[1-(1-methyl-cyclopropanecarbonyl)-piperidin-4-ylmethyl]-phenyl}-urea; use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and tumor necrosis factor (TNF) | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7511145-B2 | Bicyclic heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2009-03-26 | — | — | US | disclosed |
| US-20090053641-A1 | CHARGE CONTROL AGENT AND RELATED ART | ORIENT CHEMICAL INDUSTRIES, LTD. (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-1862860-A1 | CHARGE CONTROL AGENT AND RELATED TECHNIQUE | Orient Chemical Industries, Ltd. (JP) | 2007-12-05 | — | — | EP | disclosed |
| WO-2005012288-A1 | BICYCLIC IMIDAZOL DERIVATIVES AGAINST FLAVIVIRIDAE | GENELABS TECHNOLOGIES, INC (US) | 2005-02-10 | — | — | WO | disclosed |
| WO-2004100946-A1 | 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| US-20040059136-A1 | 7-carboxy-flavone derivatives preparation method and therapeutic use | NEGMA-LERADS (FR) | 2004-03-25 | — | — | US | disclosed |
| US-5399584-A | Preventing gastrointestinal damage caused by nonsteroidal antiinflammatory drugs | THE PROCTER & GAMBLE COMPANY (US) | 1995-03-21 | — | — | US | disclosed |
| US-4157334-A | ANTIALLERGENS, SPASMOLYTIC | CARLO ERBA S. P. A. (IT) | 1979-06-05 | — | — | US | disclosed |
| US-4157334-A | ANTIALLERGENS, SPASMOLYTIC | CARLO ERBA S. P. A. (IT) | 1979-06-05 | — | — | US | disclosed |
| US-4148900-A | ANTIALLERGIC | CARLO ERBA S.P.A. (IT) | 1979-04-10 | — | — | US | disclosed |
| US-4115567-A | TREATMENT OF ALLERGIES | CARLO ERBA S. P. A. (IT) | 1978-09-19 | — | — | US | disclosed |
| US-4083953-A | ANTIALLERGENS | CARLO ERBA, S.P.A. (IT) | 1978-04-11 | — | — | US | disclosed |
| US-4065467-A | ANTIALLERGENS, ANTIULCER AGENTS, TREATMENT OF RESPIRATORY SYSTEM AND PULMONARY DISORDERS | CARLO ERBA, S. P. A. (IT) | 1977-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040059136-A1 | 7-carboxy-flavone derivatives preparation method and therapeutic use | BCOR, CYP7B1, CYP21A2 | TNKS 4664/4885PLA2G2A 3991/4885PLA2G4A 3478/4885 |
| US-20090053641-A1 | CHARGE CONTROL AGENT AND RELATED ART | H1-4, CECR2, DOT1L | TNKS 561/4885PLA2G2A 1030/4885PLA2G4A 1587/4885 |
| US-20100226931-A1 | Compounds for immunopotentiation | LY96, ICOS, PDCD1 | TNKS 1059/4885PLA2G2A 3680/4885PLA2G4A 2676/4885 |
| US-20090081165-A1 | BICYCLIC HETEROARYL DERIVATIVES | HAVCR2, MAVS, ZC3HAV1 | TNKS 2808/4885PLA2G2A 3190/4885PLA2G4A 2465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.